AbbVie is one of America's most prominent biopharmaceutical companies, spun out of Abbott Laboratories in 2013 and built around a commercial drug portfolio of considerable scale and reach. Listed on the NYSE under the ticker ABBV, the company is perhaps best known as the maker of Humira, for many years the world's best-selling prescription medicine, though its strategic priority in recent years has been diversifying beyond Humira as biosimilar competition has eroded that franchise.
The diversification effort has been substantial. AbbVie's acquisitions of Allergan and a series of oncology and immunology assets have broadened the pipeline meaningfully, with Skyrizi and Rinvoq emerging as the next generation of growth drivers. For traders, AbbVie is an interesting combination of defensive pharmaceutical income: the company has a strong dividend track record and binary event risk around clinical trial outcomes and regulatory decisions that can move the share price sharply in either direction.
Please note this is marketing communication, not recommendation or advice.
računi klijenata
FxPro pruža usluge online trgovine korisnicima još od 1999. i trenutno posluje u 173 države svijeta.
Nagrade
FxPro u svom polju stalno dobiva priznanja te je do danas osvojio više od 145 međunarodnih nagrada koje prepoznaju kvalitetu njegovih usluga.
služba za korisnike
Naša marljiva ekipa podrške koja govori više jezika neprestano se trudi kako bi vam pružila iznimnu razinu pomoći.
regulacija djelatnosti
FxPro posluje pod strogim regulatornim nadzorom u više jurisdikcija, uključujući ovlaštenje FCA u Ujedinjenom Kraljevstvu — jednog od najpouzdanijih financijskih regulatora na globalnoj razini.
